logo
Travelling caravan couple catch glimpse of rarely seen creature in shallows: 'Fascinating'

Travelling caravan couple catch glimpse of rarely seen creature in shallows: 'Fascinating'

Yahoo2 days ago

There's no shortage of fascinating wildlife in Australia. Sometimes, you just need to know where to look.
For those travelling the continent like Mariella and Dougal, who are constantly on the lookout for animals, there's plenty to fill your days with. According to figures from the Australian federal Department of Environment, there is an estimated 566,000 living species in Australia, with only about 147,000 having been previously described.
"Since hitting the road, we've made it a mission to photograph every species we come across," Mariella told Yahoo News Australia.
"We're enthusiastic naturalists and passionate wildlife photographers, so any opportunity to document unique wildlife encounters is a real thrill for us."
And it's been a thrill they've been chasing for years now, joining the growing number of people in Australia that live a nomadic lifestyle.
"During Covid, we made the decision to buy a caravan and hit the road, and we haven't looked back since," she said.
While Mariella is from Italy, she's been living in Australia for the past decade and met Dougal in his hometown of Airlie Beach in Queensland.
"We left Airlie Beach about four years ago and have been on the move ever since," she explained to Yahoo. "We live full-time in our off-road caravan, which has been amazing. It gives us the freedom to change our backyard often."
Travelling couple reveal 'hardest thing' about life on the road
Aussie traveller's plea to every nine-to-five worker in the country
Aussie man 'living out of a van' reveals hidden truth behind trend
The couple is currently in Katherine, in the Northern Territory, before heading to Darwin to begin some work. Mariella is a qualified teacher aide while Dougal is a carpenter but has just been hired as a nature guide.
"We usually take jobs that offer a place to park the van, or we connect with people happy to share their properties in exchange for a contribution. Sometimes we stay with friends, it's a flexible, community-based lifestyle and we absolutely love it."
And, of course, it offers plenty of opportunity to have some wild encounters.
One of those instances was shared on their social media this week, with the couple coming across the rather "amazing" algae octopus, which given the creature's camouflaging prowess, is easier said than done.
"We're both underwater photographers and love chasing critters. We're equally obsessed with the big guys like manta rays, but it's the hidden world of small creatures that really captivates us," Mariella said.
The pair managed to notice the nocturnal octopus underneath a piece of driftwood while enjoying a reef walk near a remote spot called Portland Roads, about 15 minutes from Lockhart River in Queensland.
"They're such fascinating and intelligent animals, and it was a treat to spot one in the middle of the day since they're typically nocturnal," Mariella said.
"The algae octopus (Abdopus aculeatus) is known for its ability to camouflage incredibly well, often mimicking algae or rubble on the seafloor. It's one of the few octopus species known to walk on two arms — almost like tiptoeing across the seabed.
"Their behaviour and adaptability never cease to amaze us."
Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA OKs new COVID-19 vaccine for 65 and older, others with conditions
FDA OKs new COVID-19 vaccine for 65 and older, others with conditions

UPI

time30 minutes ago

  • UPI

FDA OKs new COVID-19 vaccine for 65 and older, others with conditions

A vial of the Moderna COVID-19 vaccine in the Meuhedet Clinic in Jerusalem on January 3, 2022. The FDA approved a new version of the vaccine on Friday. File photo by Debbie Hill/UPI | License Photo May 31 (UPI) -- The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened vaccine standards for the virus. The FDA announced Friday that mNEXSPIKE can be given to adults 65 and older and those 12 to 64 with at least one underlying condition that could put them at risk of severe infection. Recipients also must have been previously vaccinated for COVID-19. The company, headquartered in Cambridge, Mass., said Saturday it expects to have the vaccine available for the 2025-2026 respiratory virus season. Moderna also produces Spikevax for COVID-19, and mRESVIA for the respiratory syncytial virus, or RSV. "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," Stéphane Bancel, chief executive officer of Moderna, said. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." STAT reported the next-generation COVID-19 vaccine uses a refined target to generate antibodies against the SARS-CoV-2 virus. The dose is one-fifth the doage used in Spikevax, the current vaccine. Moderna conducted a randomized, observer-blind Phase 3 clinical trial of approximately 11,400 participants aged 12 years and older to test the mRNA-1283. The primary efficacy was to demonstrate the vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared with Spikevax, Moderna's updated COVID-19 vaccine approved on Sept. 6, 2024. The new vaccine showed a 9.3% higher relative vaccine efficacy than the mRNA-1273 in individuals aged 12 years and older. It was 13.5% better in adults aged 65 and older. In the Phase 3 trial, the most common side effects were injection site pain, fatigue, headache and myalgia. The company said there is a very small chance that mNEXSPIKE could cause a severe allergic reaction, usually within a few minutes to 1 hour after getting a dose of mNEXSPIKE. Myocarditis, which is inflammation of the heart muscle, and pericarditis, which is inflammation of the lining outside the heart, have occurred in some people who have received mRNA COVID-19 vaccines, Moderna said. Of those with problems, they are among males12 through 24. The FDA has asked Moderna to conduct post-marketing studies to continue to evaluate the safety and effectiveness of the product. This includes a study on the outcomes of pregnant people and their babies when the vaccine was administered during pregnancy. The study is to be submitted by the end of 2032. Pfizer was the first COVID-19 vaccine to receive emergency approval in December 2020 and Moderna was followed one week later. The first COVID-19 cases were reported in the United States in January 2020. The FDA first granted Pfizer-BioNTech full COVID-19 approval for those 12 and older in August 2021 and Moderna in January 2022. They remain available under emergency use authorization for children as young as 6 months. On Friday, the Centers for Disease Control and Prevention said children without underlying health conditions "may receive" a COVID-19 vaccine, contradicting a directive by Health and Human Services Secretary Robert F. Kennedy Jr. earlier in the week. The CDC updated the childhood immunization schedule published late Thursday. Kennedy, who said the agency would stop recommending the shots for healthy children, noted the guidelines would be changed. The new schedule also requires health insurance companies, Medicare and Medicaid plans to continue to cover the vaccines for children. COVID-19 shots during pregnancy are listed as "No Guidance/Not Applicable," where they were previously recommended for all pregnant adults. Earlier this month, the FDA approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay. The agency approved the vaccine only for people 65 and older and those 12 and older with at least one underlying condition at a higher risk of severe illness. This week, HHS notified Moderna that it was canceling contracts worth $766 million to develop, test and license vaccines for flu subtypes that could trigger future pandemics, including the dangerous H5N1 bird flu virus. The first COVID-19 case was reported in the United States on Jan. 20, 2020. About 23% of U.S. adults are estimated to be up to date with the vaccine, according to the CDC through April. For children 6 months and up to 18, it is an estimated 13.%, the CDC reported.

FDA approves Moderna's new lower-dose COVID-19 vaccine

timean hour ago

FDA approves Moderna's new lower-dose COVID-19 vaccine

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax — by refining its immune target. The approval 'adds an important new tool to help protect people at high risk of severe disease from COVID-19,' Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the U.S. has handled COVID-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective — and more by some measures — than the original shot, the company said. The news came just days after the Trump administration canceled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

FDA approves Moderna's new lower-dose COVID-19 vaccine
FDA approves Moderna's new lower-dose COVID-19 vaccine

Chicago Tribune

timean hour ago

  • Chicago Tribune

FDA approves Moderna's new lower-dose COVID-19 vaccine

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax — by refining its immune target. The approval 'adds an important new tool to help protect people at high risk of severe disease from COVID-19,' Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the U.S. has handled COVID-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective — and more by some measures — than the original shot, the company said. The news came just days after the Trump administration canceled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store